These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 20964464)
21. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Rodda J; Morgan S; Walker Z Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824 [TBL] [Abstract][Full Text] [Related]
22. Treatment of Alzheimer's disease in the long-term-care setting. Smith DA Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308 [TBL] [Abstract][Full Text] [Related]
23. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it? Bullock R; Connolly C Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158 [No Abstract] [Full Text] [Related]
24. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943 [TBL] [Abstract][Full Text] [Related]
25. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Herrmann N; Binder C; Dalziel W; Smyth S; Camacho F Drugs Aging; 2009; 26(5):403-7. PubMed ID: 19552492 [TBL] [Abstract][Full Text] [Related]
26. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease? Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283 [TBL] [Abstract][Full Text] [Related]
27. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Sadowsky CH; Dengiz A; Olin JT; Koumaras B; Meng X; Brannan S; Am J Alzheimers Dis Other Demen; 2009; 24(3):267-75. PubMed ID: 19293130 [TBL] [Abstract][Full Text] [Related]
28. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542 [TBL] [Abstract][Full Text] [Related]
29. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420 [TBL] [Abstract][Full Text] [Related]
30. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484 [TBL] [Abstract][Full Text] [Related]
31. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Robert P Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826 [TBL] [Abstract][Full Text] [Related]
32. Current and emerging pharmacological treatment options for dementia. Ringman JM; Cummings JL Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956 [TBL] [Abstract][Full Text] [Related]
33. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine? Sharma JC Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537 [No Abstract] [Full Text] [Related]
34. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Aguglia E; Onor ML; Saina M; Maso E Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102 [TBL] [Abstract][Full Text] [Related]
36. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Thompson S; Lanctôt KL; Herrmann N Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298 [TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Noetzli M; Eap CB Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070 [TBL] [Abstract][Full Text] [Related]
38. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. Seltzer B J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488 [TBL] [Abstract][Full Text] [Related]
39. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. Wattmo C; Paulsson E; Minthon L; Londos E Clin Interv Aging; 2013; 8():329-39. PubMed ID: 23682212 [TBL] [Abstract][Full Text] [Related]
40. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]